Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride

Giuseppe Derosa, Arrigo Francesco Giuseppe Cicero, Angela D'Angelo, Antonio Gaddi, Pietro Dario Ragonesi, Mario Nello Piccinni, Sibilla Salvadeo, Leonardina Ciccarelli, Fabio Pricolo, Morena Ghelfi, Ilaria Ferrari, Lorenza Montagna, Roberto Fogari

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The aim of our study was to compare the long-term effect of pioglitazone and rosiglitazone on blood pressure control of diabetic patients with metabolic syndrome treated with glimepiride. We evaluated 91 type 2 diabetic patients with metabolic syndrome. All were required to have been diagnosed as diabetic for at least 6 months, and to have failed to achieve glycemic control by dietary changes and the maximum tolerated dose of the oral hypoglycemic agents sulfonylureas or metformin. All patients took a fixed dose of 4 mg/day glimepiride. We administered pioglitazone (15 mg/day) or rosiglitazone (4 mg/day) for 12 months in a randomized, double-blind fashion, and evaluated body mass index (BMI), glycemic control, blood pressure and heart rate (HR) throughout the treatment period. A total of 87 patients completed the study and were randomized to receive double-blind treatment with pioglitazone or rosiglitazone. An increase in BMI was observed after 12 months (p1c), mean fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), and postprandial plasma insulin (PPI) in both treatment groups (p

Original languageEnglish
Pages (from-to)917-924
Number of pages8
JournalHypertension Research
Volume28
Issue number11
DOIs
Publication statusPublished - Nov 2005

Fingerprint

glimepiride
rosiglitazone
pioglitazone
Blood Pressure
Fasting
Body Mass Index
Insulin
Glucose
Maximum Tolerated Dose
Metformin
Hypoglycemic Agents
Therapeutics
Heart Rate
2,4-thiazolidinedione

Keywords

  • Glimepiride
  • Metabolic syndrome
  • Pioglitazone
  • Rosiglitazone
  • Thiazolidinediones

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. / Derosa, Giuseppe; Cicero, Arrigo Francesco Giuseppe; D'Angelo, Angela; Gaddi, Antonio; Ragonesi, Pietro Dario; Piccinni, Mario Nello; Salvadeo, Sibilla; Ciccarelli, Leonardina; Pricolo, Fabio; Ghelfi, Morena; Ferrari, Ilaria; Montagna, Lorenza; Fogari, Roberto.

In: Hypertension Research, Vol. 28, No. 11, 11.2005, p. 917-924.

Research output: Contribution to journalArticle

Derosa, G, Cicero, AFG, D'Angelo, A, Gaddi, A, Ragonesi, PD, Piccinni, MN, Salvadeo, S, Ciccarelli, L, Pricolo, F, Ghelfi, M, Ferrari, I, Montagna, L & Fogari, R 2005, 'Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride', Hypertension Research, vol. 28, no. 11, pp. 917-924. https://doi.org/10.1291/hypres.28.917
Derosa, Giuseppe ; Cicero, Arrigo Francesco Giuseppe ; D'Angelo, Angela ; Gaddi, Antonio ; Ragonesi, Pietro Dario ; Piccinni, Mario Nello ; Salvadeo, Sibilla ; Ciccarelli, Leonardina ; Pricolo, Fabio ; Ghelfi, Morena ; Ferrari, Ilaria ; Montagna, Lorenza ; Fogari, Roberto. / Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. In: Hypertension Research. 2005 ; Vol. 28, No. 11. pp. 917-924.
@article{0c25043617344c7488a3694dbec5ddbe,
title = "Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride",
abstract = "The aim of our study was to compare the long-term effect of pioglitazone and rosiglitazone on blood pressure control of diabetic patients with metabolic syndrome treated with glimepiride. We evaluated 91 type 2 diabetic patients with metabolic syndrome. All were required to have been diagnosed as diabetic for at least 6 months, and to have failed to achieve glycemic control by dietary changes and the maximum tolerated dose of the oral hypoglycemic agents sulfonylureas or metformin. All patients took a fixed dose of 4 mg/day glimepiride. We administered pioglitazone (15 mg/day) or rosiglitazone (4 mg/day) for 12 months in a randomized, double-blind fashion, and evaluated body mass index (BMI), glycemic control, blood pressure and heart rate (HR) throughout the treatment period. A total of 87 patients completed the study and were randomized to receive double-blind treatment with pioglitazone or rosiglitazone. An increase in BMI was observed after 12 months (p1c), mean fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), and postprandial plasma insulin (PPI) in both treatment groups (p",
keywords = "Glimepiride, Metabolic syndrome, Pioglitazone, Rosiglitazone, Thiazolidinediones",
author = "Giuseppe Derosa and Cicero, {Arrigo Francesco Giuseppe} and Angela D'Angelo and Antonio Gaddi and Ragonesi, {Pietro Dario} and Piccinni, {Mario Nello} and Sibilla Salvadeo and Leonardina Ciccarelli and Fabio Pricolo and Morena Ghelfi and Ilaria Ferrari and Lorenza Montagna and Roberto Fogari",
year = "2005",
month = "11",
doi = "10.1291/hypres.28.917",
language = "English",
volume = "28",
pages = "917--924",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride

AU - Derosa, Giuseppe

AU - Cicero, Arrigo Francesco Giuseppe

AU - D'Angelo, Angela

AU - Gaddi, Antonio

AU - Ragonesi, Pietro Dario

AU - Piccinni, Mario Nello

AU - Salvadeo, Sibilla

AU - Ciccarelli, Leonardina

AU - Pricolo, Fabio

AU - Ghelfi, Morena

AU - Ferrari, Ilaria

AU - Montagna, Lorenza

AU - Fogari, Roberto

PY - 2005/11

Y1 - 2005/11

N2 - The aim of our study was to compare the long-term effect of pioglitazone and rosiglitazone on blood pressure control of diabetic patients with metabolic syndrome treated with glimepiride. We evaluated 91 type 2 diabetic patients with metabolic syndrome. All were required to have been diagnosed as diabetic for at least 6 months, and to have failed to achieve glycemic control by dietary changes and the maximum tolerated dose of the oral hypoglycemic agents sulfonylureas or metformin. All patients took a fixed dose of 4 mg/day glimepiride. We administered pioglitazone (15 mg/day) or rosiglitazone (4 mg/day) for 12 months in a randomized, double-blind fashion, and evaluated body mass index (BMI), glycemic control, blood pressure and heart rate (HR) throughout the treatment period. A total of 87 patients completed the study and were randomized to receive double-blind treatment with pioglitazone or rosiglitazone. An increase in BMI was observed after 12 months (p1c), mean fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), and postprandial plasma insulin (PPI) in both treatment groups (p

AB - The aim of our study was to compare the long-term effect of pioglitazone and rosiglitazone on blood pressure control of diabetic patients with metabolic syndrome treated with glimepiride. We evaluated 91 type 2 diabetic patients with metabolic syndrome. All were required to have been diagnosed as diabetic for at least 6 months, and to have failed to achieve glycemic control by dietary changes and the maximum tolerated dose of the oral hypoglycemic agents sulfonylureas or metformin. All patients took a fixed dose of 4 mg/day glimepiride. We administered pioglitazone (15 mg/day) or rosiglitazone (4 mg/day) for 12 months in a randomized, double-blind fashion, and evaluated body mass index (BMI), glycemic control, blood pressure and heart rate (HR) throughout the treatment period. A total of 87 patients completed the study and were randomized to receive double-blind treatment with pioglitazone or rosiglitazone. An increase in BMI was observed after 12 months (p1c), mean fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), and postprandial plasma insulin (PPI) in both treatment groups (p

KW - Glimepiride

KW - Metabolic syndrome

KW - Pioglitazone

KW - Rosiglitazone

KW - Thiazolidinediones

UR - http://www.scopus.com/inward/record.url?scp=31744442785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31744442785&partnerID=8YFLogxK

U2 - 10.1291/hypres.28.917

DO - 10.1291/hypres.28.917

M3 - Article

VL - 28

SP - 917

EP - 924

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 11

ER -